Featured image: A laboratory microscope illustrates genetic-medicine research. Contextual photograph; not equipment from the WVE-006 trial. Photo: Ousa Chea / Unsplash. Unsplash licence.
A genetic medicine can change the instructions a cell reads without permanently changing the DNA that stores them. RNA editing is bringing that idea into human trials, with a different balance between durability, dosing and control.
On 1 October 2026, Wave Life Sciences said FDA feedback supported key aspects of a planned registrational pathway for WVE-006 in alpha-1 antitrypsin deficiency. The company is planning a two-year trial, with a one-year interim analysis for a possible accelerated-approval application. This is a development plan reported by the sponsor, not an FDA approval. Read Wave’s update.
One inherited error can affect two organs
Alpha-1 antitrypsin, or AAT, helps protect lung tissue from an enzyme released by immune cells. Variants in the SERPINA1 gene can leave too little functional protein available. An abnormal form can also accumulate in the liver, creating a second source of damage. MedlinePlus explanation of the condition.
WVE-006 is being developed for people with two copies of the Z variant, often written Pi*ZZ. The intended effect is to increase normal M-AAT protein while reducing production of the abnormal Z-AAT form. Those are molecular objectives; they must still translate into meaningful protection of organs.
This makes the programme different from simply adding more protein to blood. It attempts to change which version the patient’s own cells produce, while leaving the underlying inherited DNA sequence in place.
The edit happens in a temporary working copy
RNA carries working instructions copied from DNA. In this approach, a short synthetic nucleic-acid molecule guides a naturally occurring RNA-editing enzyme to a chosen position. ADAR, short for adenosine deaminase acting on RNA, can change adenosine into inosine, which the cell reads like guanosine.
The foundation is established laboratory research. A 2019 Nature Biotechnology paper demonstrated engineered RNAs that recruit endogenous ADAR in cells, including patient-derived cells. Those experiments were not a clinical trial of WVE-006. They explain how an RNA guide can enlist machinery already present inside a cell. Read the original ADAR-recruitment study.
An edited RNA molecule eventually turns over, unlike a permanent DNA edit. That creates potential for dose adjustment, but also a need to understand how long the effect lasts and how often treatment must be repeated. Transience alone does not establish safety.
Human biomarker results are promising but limited
In a separate update on 18 May 2026, Wave reported that normal M-AAT made up 64% of total AAT and abnormal Z-AAT fell by 71% in the 200 mg biweekly cohort. It described sustained editing effects at least three months after the last dose. The figures are sponsor-reported interim biomarker results, not evidence of a cure or proven prevention of lung and liver disease. Interim clinical-data announcement.
RestorAATion-2 is a Phase Ib/IIa, open-label, non-randomised dose study. Its registry lists estimated enrolment of 24 and an active, not recruiting status. The entry was last updated on 14 April 2026; its estimated completion date is not confirmation that the study has finished. Check the registered study.
Open-label means investigators and participants know the treatment. Small dose cohorts are useful for detecting biological activity and characterising safety, but they cannot provide the certainty of a sufficiently powered comparative trial.
The next trial must connect a protein signal to health
Wave’s October announcement says the proposed interim analysis would use AATD biomarkers. A biomarker is a measured biological signal. The planned two-year study would also support a potential full-approval pathway, according to the company. The final design and the eventual results remain separate milestones. Proposed registrational approach.
The important question is whether changing circulating protein improves outcomes that matter to people over time, while remaining tolerable with repeated dosing. Assay consistency, organ function, adverse events and durability will all affect how persuasive that evidence becomes.
RNA editing has now produced a human molecular signal and a proposal for a stronger clinical test. The responsible next claim is about development progress: the larger experiment has to earn the clinical conclusion.
Leave a Reply